Skip to main content
Clinical Trials/NCT04940403
NCT04940403
Not yet recruiting
Not Applicable

BurtVision™ for Arm Rehabilitation in Chronic Stroke Survivors: a Comparison of Unimanual vs. Unimanual and Bimanual Tasks During Robot-assisted Arm Training

Spaulding Rehabilitation Hospital0 sites38 target enrollmentJune 1, 2023
ConditionsStroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Spaulding Rehabilitation Hospital
Enrollment
38
Primary Endpoint
Motor Activity Log- Amount of Use
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

The focus of this study is to perform a preliminary assessment of the efficacy of the BurtVision system. While the Burt robotic-arm assists the patient's upper-limb in their movements, BurtVision will allow the patient to perform unimanual and bimanual activities while leveraging augmented reality games. The investigators will compare clinical outcomes when the BurtVisions ystem is used for training solely relying on unimanual tasks vs. when it is used for training relying on both unimanual and bimanual tasks.

Detailed Description

The proposed study is a single-blinded randomized clinical trial to evaluate the effect of using the BurtVistion on motor gains after robot-assisted upper-limb. Study participants (stroke survivors) will be recruited at the Spaulding Rehabilitation Hospital - Boston. Subjects will be randomly assigned to one of the two different groups: unimanual or unimanual + bimanual arm therapy using a block-randomized allocation procedure to ensure important covariates, such as baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) scores and chronicity, are balanced between groups.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
June 1, 2026
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Spaulding Rehabilitation Hospital
Responsible Party
Principal Investigator
Principal Investigator

Paolo Bonato

Associate Professor, HMS and Director, Motion Analysis Laboratory

Spaulding Rehabilitation Hospital

Eligibility Criteria

Inclusion Criteria

  • Male or female, 18-80 years old;
  • Unilateral ischemic or hemorrhagic stroke at least 6 months and no more than 5 years prior to study enrollment;
  • Upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 12 and 40;
  • Some active pro-supination range of motion;
  • Some active metacarpal-phalangeal joint in the hemiparetic hand;
  • Intact cognitive function to understand the robotic therapy procedures (MMSE\>23 and able to follow 3 step command) during initial evaluation visit;

Exclusion Criteria

  • Undergoing upper-limb rehabilitation therapy during the period of the study.
  • Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe use of the robotic system;
  • Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject's ability to play the interactive games (as assessed with the line bisection test);
  • Severe proprioceptive deficits that impair the ability to process haptic or visual feedback, as assessed by physical examination during screening;
  • Communication impairments such aphasia that impair the subject's ability of providing feedback (as reported by a physician in his/her medical record);
  • Individuals with open wounds or recent fracture (\<3 months) in the upper extremity, fragile skin or active infection;
  • Upper-extremity orthopedic injuries or severe pain resulting in movement limitations.

Outcomes

Primary Outcomes

Motor Activity Log- Amount of Use

Time Frame: Data will be collected at baseline and at 7-8 weeks

Self-reported measures of upper extremity activity performance in daily life (amount of use)

Secondary Outcomes

  • Wolf Motor Function Test(Data will be collected at baseline and at 7-8 weeks)
  • Fugl-Meyer Assessment, Upper-Extremity portion(Data will be collected at baseline and at 7-8 weeks)
  • Stroke Impact Scale(Data will be collected at baseline and at 7-8 weeks)
  • Upper-Extremity Accelerometry(Data will be collected at baseline and at 7-8 weeks)
  • Motor Activity Log- Quality of Use(Data will be collected at baseline and at 7-8 weeks)

Similar Trials